ADIL - ADIAL PHARMACEUTICALS, INC.
IEX Last Trade
1.06
0.030 2.830%
Share volume: 0
Last Updated: Thu 26 Dec 2024 07:55:19 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$1.03
0.03
2.91%
Fundamental analysis
29%
Profitability
30%
Dept financing
16%
Liquidity
50%
Performance
25%
Performance
5 Days
1.94%
1 Month
5.00%
3 Months
4.97%
6 Months
-4.55%
1 Year
-46.43%
2 Year
-81.00%
Key data
Stock price
$1.06
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.86 - $4.17
52 WEEK CHANGE
-$40.68
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Cary J. Claiborne
Region: US
Website: adialpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: adialpharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.
Recent news